Effectiveness of Obesity Management Education for Healthcare Professionals: A Rapid Review and Meta-Analysis.

Clin ObesSep 12, 2026
Clinical ResearchEndocrinologyInternal Medicine (General)Family Medicine

Rebecca Wu, Srividya Adapa, Maria Agaliotis et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the effectiveness of structured obesity management education for healthcare professionals (HCPs). Eighteen studies were included, revealing a significant improvement in practice competencies (SMD = 0.41, 95% CI 0.12-0.70, p < 0.01). The analysis indicated that longer interventions (≥ 4 hours) yielded greater improvements in HCP competencies.

Key findings

  • Pooled analysis showed a significant improvement in practice competencies (SMD = 0.41, p < 0.01).
  • Randomized controlled trials demonstrated a larger effect (SMD = 0.53, p = 0.01) compared to non-RCTs.
  • Interventions lasting ≥ 4 hours produced significant effects (SMD = 0.68, p < 0.01).

Why it matters

Improving HCP competencies in obesity management is crucial for enhancing patient care. Structured education can address gaps in training and confidence, potentially leading to better patient outcomes in obesity treatment.

Source

PubMed · PMID 42728234

Published in Clin Obes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.